AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-KOCT 151 min read$JSPR

Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy Initial Stage 1 data evaluating vensobafusp alfa in IgAN expected by year-end 2026 Announces expansion cohort i

Original reporting
SEC EDGAR 8-K
Published Oct 15, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 12:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$JSPR
Neutral
medium confidence
Mentioned
$JSPR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JSPRNeutralLow
01

Why it matters

The enrollment completion is a forward‑looking milestone; investors will watch for the year‑end interim data release.

02

Market read

The announcement may generate modest buying interest ahead of data, but the impact is contingent on trial outcomes.

03

What to watch

The study also includes cohorts for C3G and FSGS, which could broaden the drug's market potential.

Relevance 7/10Novelty 7/10Timing: today

Background

Jasper Therapeutics (Nasdaq: JSPR) is a clinical‑stage biotech focused on complement‑targeted therapies for immune‑mediated kidney diseases.

Company-level read

Ticker impact

$JSPRNeutralMedium confidence
Context

Jasper Therapeutics announced completion of enrollment for the IgA nephropathy cohort of its Phase 2 basket study, a new milestone for the drug candidate.

Expected impact

potential upside as investors price in upcoming interim data; downside risk if data disappoints

Evidence & confidence

The news is a primary disclosure of a trial milestone; no data yet, so market reaction will depend on future results.

Market effects

Sector

Adds to the pipeline momentum for renal‑targeted biotech firms.

Regional

Limited to US‑listed biotech investors.

Global

Modest; primarily relevant to specialty pharma investors.

Counterpoint

What could challenge this read

If the trial faces delays or negative interim data, the stock could fall sharply despite the enrollment news.

Key entities

  • company
    Jasper Therapeutics

    Clinical‑stage biotech developing vensobafusp alfa.

  • person
    Greg Keenan, M.D.

    Chief Medical Officer of Jasper Therapeutics.

Read at source← All news

Related articles

AUG 17
$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

yahoo.com4 min
AUG 14
$JSPRMed

Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Jasper Therapeutics, Inc. (JSPR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders

SEC EDGAR 8-K6 min
AUG 14
$JSPRMedAI 8/10

Jasper Therapeutics Secures $132M In Financing; Advances Post-Kira Clinical Pipeline

Jasper Therapeutics (JSPR) reported Q2 2026 results and a corporate update after completing its all-stock acquisition of Kira Pharmaceuticals on July 16, 2026. The company raised about $132M via a private placement of non-voting convertible preferred stock. Cash was $7.3M at June 30. Net loss was $2.8M. Pipeline updates include KP-104, briquilimab, and KP-701.

rttnews.com6 min
JUL 20
$JSPRMedAI 9/10

Jasper Therapeutics merges with Kira Pharmaceuticals

Jasper Therapeutics completed an all-stock acquisition of Kira Pharmaceuticals, forming a combined Nasdaq-listed company under ticker JSPR. The deal includes a $132M private placement and a $12M Mirador out-licensing payment on signing, funding operations through H2 2028. Pipeline includes KP-104, briquilimab, and KP-701 with upcoming clinical milestones.

pharmatimes.com5 min
JUL 17
$JSPRMedAI 8/10

Jasper Closes Kira Deal, Extends Cash Runway - Jasper Therapeutics (NASDAQ:JSPR)

Jasper Therapeutics (NASDAQ:JSPR) closed a deal with Kira and completed a private placement of non-voting convertible preferred stock raising about $132 million gross. The company expects cash to fund operations through 2H 2028. Jasper out-licensed Kira’s KP-301 and KP-402 to Mirador for $12 million upfront plus milestones. JSPR shares rose 20.67% to $0.9250.

benzinga.com5 min